tiprankstipranks
Trending News
More News >

Akeso’s Ebdarokimab Receives Approval for Psoriasis Treatment in China

Story Highlights
Akeso’s Ebdarokimab Receives Approval for Psoriasis Treatment in China

Confident Investing Starts Here:

Akeso, Inc. ( (HK:9926) ) just unveiled an update.

Akeso, Inc. announced that the National Medical Products Administration of China has approved the new drug application for Ebdarokimab, a treatment for moderate to severe plaque psoriasis. This approval marks a significant advancement for Akeso as it is their first Class 1 new drug approved for autoimmune diseases and the second non-oncology drug to receive marketing approval. Ebdarokimab has shown positive short-term and sustained long-term efficacy, significant improvement in patients’ quality of life, and a good safety profile. The drug is poised to address the growing needs of the psoriatic population in China, offering a cost-effective and convenient treatment option.

More about Akeso, Inc.

Akeso, Inc. is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. It specializes in developing innovative drugs, particularly in the field of autoimmune diseases and oncology, with a market focus on providing effective and patient-centric therapeutic solutions.

YTD Price Performance: 36.66%

Average Trading Volume: 12,473,628

Technical Sentiment Signal: Sell

Current Market Cap: HK$74.45B

For detailed information about 9926 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App